- Company
- Novo Nordisk appoints Sasha Semienchuk as new GM
- by Eo, Yun-Ho Oct 19, 2022 05:48am
- On the 18th, Novo Nordisk announced that it has appointed Sasha Semienchuk as the VP and General Manager of its Korean subsidiary effective in October. Sasha Semienchuk owns over 20 years of experience in healthcare across sales, marketing, research, and management at multinational pharmaceutical companies and startups in 7 countries on t
- Opinion
- [Desktop] Increase accessibility by beating generic prices
- by Kim, Jung-Ju Oct 19, 2022 05:48am
- The direction of the government's guarantee policy has been consistent. It is to reduce finances by preventing inefficient operations and increase patient accessibility with sufficient funds. It's a kind of 'trade-off' way. At one time, there was a massive plan to strengthen the search for hospitals and pharmacies that illegally borrow licens
- Company
- Forxiga & Jardiance are expected to surpass 100 billion won
- by Nho, Byung Chul Oct 19, 2022 05:48am
- The SGLT-2-inhibited original diabetes treatment market recorded 53 billion won in the first half of this year, which is expected to surpass 100 billion won by the end of this year. The SGLT-2 original drug market was divided into Forxiga and Beringer Ingelheim Jardiance, and sales of 22.1 billion won and 30.9 billion won in the first half, r
- Policy
- Is it possible to benefit from the K-CAB 4th indication?
- by Lee, Tak-Sun Oct 17, 2022 10:52pm
- Attention is focusing on whether HK inno. N's new drug K-CAB for gastroesophageal reflux disease will succeed in providing additional indications. Currently, K-CAB is being reimbursed to treat erosive and non-erosive gastroesophageal reflux disease and gastric ulcer. In March 2019, K-CAB, which was first applied to the treatment of erosive an
- Opinion
- [Reporter’s View] The key to the ‘PE Exemption’ issue
- by Eo, Yun-Ho Oct 17, 2022 10:52pm
- The cries that the improvement reduces rather than expand benefits have reached the National Assembly. The government’s improvement plan for the special pharmacoeconomic evaluation (PE) exemption system was brought onto the chopping block at the NA audit. During the NA audit for the Health Insurance Review and Assessment Service that
- Policy
- PVA, financial resources to register new drugs, not penaltie
- by Lee, Jeong-Hwan Oct 17, 2022 10:52pm
- Regarding the criticism that PVA imposes penalties on pharmaceutical companies that produce drugs with high public demand, the Ministry of Health and Welfare countered that it is a system that contributes to improving patient accessibility through new drug insurance. The Ministry of Health and Welfare also said that it is impossible to tem
- Policy
- “No considerations made to protect generics” at NA audit
- by Lee, Jeong-Hwan Oct 17, 2022 10:52pm
- After the Ministry of Health and Welfare revealed its plan to lower the price of generics step by step at the 2022 NA Audit, the domestic pharmaceutical industry has been expressly expressing their displeasure on how pro-government the regulation is and criticized how the plan does not consider the realities of the industry. The indust
- Company
- Shingrix costs 600,000 won
- by Kim, Jin-Gu Oct 17, 2022 10:51pm
- The inoculation price of Shingrix, a shingles vaccine scheduled to be supplied in December, is expected to be around 600,000 won. It is four to five times the existing inoculation price. According to the pharmaceutical industry on the 15th, GSK and GC Pharma recently officially signed a domestic joint sales contract for Shingrix. The two comp
- Shingrix, a shingles vaccine, will be released in December
- by Oct 17, 2022 06:03am
- Shingrix, a new shingles vaccine that boasts overwhelming preventive effects, will be officially released in December. It is expected to shake the game of shingles vaccines by showing a 97% prevention effect, which is twice that of existing vaccines, and proving long-term effectiveness and safety. On the other hand, prices are more than four
- InterView
- “AstraZeneca’s sincerity in oncology drives cont. growth"
- by Eo, Yun-Ho Oct 17, 2022 06:03am
- AstraZeneca is known for its ‘sincere attitude’ towards R&D. Not only is the company in the top ranks in terms of its investment amount, but it has also always been at the forefront in terms of R&D-to-Total-revenue ratio as well. In 2021, AstraZeneca’s R&D-to-Total-revenue ratio stood at 26%, the highest in the industry. Due to their i
